Compliance with the new dietary ingredient notification requirement has been more of a problem, and a longer lasting one, for the US Food and Drug Administration than any other component of its regulatory framework for dietary supplement manufacturing.
US Supplement Industry Regulation: More Resources, Rules Needed, Or Current Tools Enough?
During Trump’s second administration and with Republican majorities currently in both chambers of Congress, FDA may find even less support than it traditionally has for appeals for additional resources to improve compliance with the NDIN requirement. Likewise for FDA request mandatory product listing requirement for supplements available to US consumers.
More from Leadership
• By
A round-up of the latest European health & wellness market moves: Maxwellia names chief operating officer; Nestle appoints marketing & sales head; Alland & Robert gets deputy general manager.
• By
Product reviews for drugs, biologics, devices, tobacco and foods could be consolidated into one office at the FDA, as part of a restructuring plan circulating that was obtained by Pink Sheet.
• By
The former principal deputy commissioner said the “decapitation” of senior leadership will make resolving internal disputes more difficult, which will slow application reviews. Woodcock also called the FDA layoffs a slow-moving catastrophe.
• By
HBW Insight catches up with PAGB CEO Michelle Riddalls to chat about the association's new five year plan. Riddalls also reflects on the successes of the last five years, including relaunching the UK Reclassification Alliance, which has published a list of Rx-to-OTC switches the government would like to see applications for. Part one of two.